Mandate

Vinge advises Capillar in connection with Sweden’s first ever de-SPAC

Capillar and the minority shareholders have entered into an agreement to sell all shares in Spolargruppen Sverige AB, a Swedish leading player in pipe lining (so-called relining) and pipe flushing, to tbd30 AB (publ), a so called SPAC (Special Purpose Acquisition Company).

In connection with the proposed transaction, a process is initiated (so-called “de-SPAC” or company combination) which includes, among other things, that Nasdaq Stockholm AB examines the intended acquisition, application for listing and change of trading venue to Nasdaq First North Growth Market within the framework of Nasdaq Stockholm's regulations regarding SPACs.

As part of the continued financing, a number of institutional and other investors, including Lannebo Fonder and Carnegie Fonder, have undertaken to subscribe for 1,500,000 new class A shares in tbd30 in a directed new share issue at SEK 100 per share.

Vinges team primarily consists of Christina Kokko, Joacim Rydergård, Hannah Kajlinger and Philip Moré (M&A), Linnéa Sellström (Equity Capital Markets) as well as Matthias Schömer and Henrik Wastenson (Tax).

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025